Tempest Therapeutics (TPST) Research & Development (2012 - 2026)

Tempest Therapeutics has disclosed Research & Development across 15 years of filings, most recently posting $1.8 million for Q2 2026.

• In Q2 2026, Research & Development fell 53.01% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $6.8 million (down 77.18% YoY), while the FY2025 annual figure was $12.6 million, down 55.73% from the prior year.
• Research & Development came in at $1.8 million for Q2 2026 at Tempest Therapeutics, up from $539000.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $10.7 million in Q4 2024 to a low of $539000.0 in Q4 2025.
• Average Research & Development over 5 years is $4.9 million, with a median of $4.7 million recorded in 2023.
• Year-over-year, Research & Development jumped 156.8% in 2024 and slumped 94.98% in 2025.
• Over 5 years, Research & Development stood at $5.8 million in 2022, then retreated by 27.8% to $4.2 million in 2023, then soared by 156.8% to $10.7 million in 2024, then tumbled by 94.98% to $539000.0 in 2025, then soared by 237.48% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.8 million in Q2 2026, $539000.0 in Q4 2025, and $570000.0 in Q3 2025.